EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.
EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.
2018 Korea CPHI, C30
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
1.
Lenvatinib mesylate , CAS#857890-39-2, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than31KG in stock, pls check:
Name:Lenvatinib mesylate
CAS#: 857890-39-2
Formula: C22H23ClN4O7S
Exact Mass:
Molecular Weight: 522.96
Elemental Analysis: C, 50.53; H, 4.43; Cl, 6.78; N, 10.71; O, 21.42; S, 6.13
Exact Mass:
Molecular Weight: 522.96
Elemental Analysis: C, 50.53; H, 4.43; Cl, 6.78; N, 10.71; O, 21.42; S, 6.13
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
2.
Lenvatinib mesylate Intermediates:
1.Lenvatinib mesylate Intermediate:Methyl 4-chloro-7-methoxyquinoline-6-carboxylate
1.Lenvatinib mesylate Intermediate:Methyl 4-chloro-7-methoxyquinoline-6-carboxylate
Cas#205448-66-4,
We have more than 43kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
2.Lenvatinib mesylate Intermediate:4-Chloro-7-methoxyquinoline-6-carboxamide
Cas#417721-36-9
We have more than 45kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
3.Lenvatinib mesylate Intermediate:1-(2-Chloro-4-hydroxyphenyl)-3-cyclopropylurea
Cas#796848-79-8
We have more than 54kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Reference：
1: Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 Apr 14. doi: 10.1002/cncr.31344. [Epub ahead of print] PubMed PMID: 29656442.
2: Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S. Lenvatinib-induced renal failure: two first-time case reports and review of literature. Expert Opin Drug Metab Toxicol. 2018 Apr 13:1-7. doi: 10.1080/17425255.2018.1461839. [Epub ahead of print] PubMed PMID: 29617171.
3: De Lisi D, De Giorgi U, Lolli C, Schepisi G, Conteduca V, Menna C, Tonini G, Santini D, Farolfi A. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? Expert Opin Drug Metab Toxicol. 2018 Mar 23:1-7. doi: 10.1080/17425255.2018.1455826. [Epub ahead of print] PubMed PMID: 29557694.
4: Groden PJ, Lee TC, Bhattacharyya S, Connors J, Lorch J. Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma. Front Med (Lausanne). 2018 Feb 23;4:220. doi: 10.3389/fmed.2017.00220. eCollection 2017. PubMed PMID: 29527527; PubMed Central PMCID: PMC5829091.
5: Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep. 2018 May;39(5):2225-2234. doi: 10.3892/or.2018.6306. Epub 2018 Mar 8. PubMed PMID: 29517103.
6: Kimura-Tsuchiya R, Sasaki E, Nakamura I, Suzuki S, Kawana S, Okouchi C, Fukushima T, Hashimoto Y, Suzuki S, Saji S. A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib. Case Rep Oncol. 2018 Feb 9;11(1):75-80. doi: 10.1159/000486569. eCollection 2018 Jan-Apr. PubMed PMID: 29515414; PubMed Central PMCID: PMC5836208.
7: Nervo A, Gallo M, Samà MT, Felicetti F, Alfano M, Migliore E, Marchisio F, Berardelli R, Arvat E, Piovesan A. Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice. Anticancer Res. 2018 Mar;38(3):1643-1649. PubMed PMID: 29491097.
8: Thomas H. Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):190. doi: 10.1038/nrgastro.2018.20. Epub 2018 Feb 28. PubMed PMID: 29487423.
9: Ferrari SM, Ruffilli I, Centanni M, Virili C, Materazzi G, Alexopoulou M, Miccoli M, Antonelli A, Fallahi P. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied. Recent Pat Anticancer Drug Discov. 2018 Feb 19. doi: 10.2174/1574892813666180220110729. [Epub ahead of print] PubMed PMID: 29468981.
10: Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PubMed PMID: 29433850.
11: Reig M, Bruix J. Lenvatinib: can a non-inferiority trial change clinical practice? Lancet. 2018 Mar 24;391(10126):1123-1124. doi: 10.1016/S0140-6736(18)30208-3. Epub 2018 Feb 9. PubMed PMID: 29433849.
12: Nishi T, Igawa A, Nishimura A, Hakamada K. [A Case of a Rupture of the Carotid Artery Caused by the Lenvatinib Medication]. Gan To Kagaku Ryoho. 2017 Nov;44(12):1610-1612. Japanese. PubMed PMID: 29394718.
13: Suyama K, Tomiguchi M, Takeshita T, Sueta A, Yamamoto-Ibusuki M, Shimokawa M, Yamamoto Y, Iwase H. Factors involved in early lenvatinib dose reduction: a retrospective analysis. Med Oncol. 2018 Jan 31;35(3):19. doi: 10.1007/s12032-018-1088-5. PubMed PMID: 29387983.
14: Lenvatinib. Aust Prescr. 2017 Dec;40(6):242-243. doi: 10.18773/austprescr.2017.070. Epub 2017 Oct 3. Review. PubMed PMID: 29375189; PubMed Central PMCID: PMC5768601.
15: Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, Cristina V, Güthner C, Zimmermann S, Weidner S, Pless M, Stenner F, Rothschild SI. Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. J Cancer. 2018 Jan 1;9(2):250-255. doi: 10.7150/jca.22318. eCollection 2018. PubMed PMID: 29344270; PubMed Central PMCID: PMC5771331.
16: Lee YS, Kim SM, Kim BW, Chang HJ, Kim SY, Park CS, Park KC, Chang HS. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells. Neoplasia. 2018 Feb;20(2):197-206. doi: 10.1016/j.neo.2017.12.003. Epub 2018 Jan 12. PubMed PMID: 29331886; PubMed Central PMCID: PMC5767911.
17: Wei X, Zhang T, Yao Y, Zeng S, Li M, Xiang H, Zhao C, Cao G, Li M, Wan R, Yang P, Yang J. Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD. Exp Eye Res. 2018 Mar;168:2-11. doi: 10.1016/j.exer.2017.12.009. Epub 2017 Dec 25. PubMed PMID: 29284110.
18: Kudo M. Lenvatinib in Advanced Hepatocellular Carcinoma. Liver Cancer. 2017 Nov;6(4):253-263. doi: 10.1159/000479573. Epub 2017 Aug 29. PubMed PMID: 29234629; PubMed Central PMCID: PMC5704706.
19: Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma. Intern Med. 2018 Apr 1;57(7):1015-1019. doi: 10.2169/internalmedicine.9593-17. Epub 2017 Dec 8. PubMed PMID: 29225265.
20: Morelli S, Puxeddu E. Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient. Drugs Context. 2017 Jul 26;6:212310. doi: 10.7573/dic.212310. eCollection 2017. PubMed PMID: 29167691; PubMed Central PMCID: PMC5699105.
2: Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S. Lenvatinib-induced renal failure: two first-time case reports and review of literature. Expert Opin Drug Metab Toxicol. 2018 Apr 13:1-7. doi: 10.1080/17425255.2018.1461839. [Epub ahead of print] PubMed PMID: 29617171.
3: De Lisi D, De Giorgi U, Lolli C, Schepisi G, Conteduca V, Menna C, Tonini G, Santini D, Farolfi A. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? Expert Opin Drug Metab Toxicol. 2018 Mar 23:1-7. doi: 10.1080/17425255.2018.1455826. [Epub ahead of print] PubMed PMID: 29557694.
4: Groden PJ, Lee TC, Bhattacharyya S, Connors J, Lorch J. Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma. Front Med (Lausanne). 2018 Feb 23;4:220. doi: 10.3389/fmed.2017.00220. eCollection 2017. PubMed PMID: 29527527; PubMed Central PMCID: PMC5829091.
5: Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep. 2018 May;39(5):2225-2234. doi: 10.3892/or.2018.6306. Epub 2018 Mar 8. PubMed PMID: 29517103.
6: Kimura-Tsuchiya R, Sasaki E, Nakamura I, Suzuki S, Kawana S, Okouchi C, Fukushima T, Hashimoto Y, Suzuki S, Saji S. A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib. Case Rep Oncol. 2018 Feb 9;11(1):75-80. doi: 10.1159/000486569. eCollection 2018 Jan-Apr. PubMed PMID: 29515414; PubMed Central PMCID: PMC5836208.
7: Nervo A, Gallo M, Samà MT, Felicetti F, Alfano M, Migliore E, Marchisio F, Berardelli R, Arvat E, Piovesan A. Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice. Anticancer Res. 2018 Mar;38(3):1643-1649. PubMed PMID: 29491097.
8: Thomas H. Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):190. doi: 10.1038/nrgastro.2018.20. Epub 2018 Feb 28. PubMed PMID: 29487423.
9: Ferrari SM, Ruffilli I, Centanni M, Virili C, Materazzi G, Alexopoulou M, Miccoli M, Antonelli A, Fallahi P. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied. Recent Pat Anticancer Drug Discov. 2018 Feb 19. doi: 10.2174/1574892813666180220110729. [Epub ahead of print] PubMed PMID: 29468981.
10: Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PubMed PMID: 29433850.
11: Reig M, Bruix J. Lenvatinib: can a non-inferiority trial change clinical practice? Lancet. 2018 Mar 24;391(10126):1123-1124. doi: 10.1016/S0140-6736(18)30208-3. Epub 2018 Feb 9. PubMed PMID: 29433849.
12: Nishi T, Igawa A, Nishimura A, Hakamada K. [A Case of a Rupture of the Carotid Artery Caused by the Lenvatinib Medication]. Gan To Kagaku Ryoho. 2017 Nov;44(12):1610-1612. Japanese. PubMed PMID: 29394718.
13: Suyama K, Tomiguchi M, Takeshita T, Sueta A, Yamamoto-Ibusuki M, Shimokawa M, Yamamoto Y, Iwase H. Factors involved in early lenvatinib dose reduction: a retrospective analysis. Med Oncol. 2018 Jan 31;35(3):19. doi: 10.1007/s12032-018-1088-5. PubMed PMID: 29387983.
14: Lenvatinib. Aust Prescr. 2017 Dec;40(6):242-243. doi: 10.18773/austprescr.2017.070. Epub 2017 Oct 3. Review. PubMed PMID: 29375189; PubMed Central PMCID: PMC5768601.
15: Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, Cristina V, Güthner C, Zimmermann S, Weidner S, Pless M, Stenner F, Rothschild SI. Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. J Cancer. 2018 Jan 1;9(2):250-255. doi: 10.7150/jca.22318. eCollection 2018. PubMed PMID: 29344270; PubMed Central PMCID: PMC5771331.
16: Lee YS, Kim SM, Kim BW, Chang HJ, Kim SY, Park CS, Park KC, Chang HS. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells. Neoplasia. 2018 Feb;20(2):197-206. doi: 10.1016/j.neo.2017.12.003. Epub 2018 Jan 12. PubMed PMID: 29331886; PubMed Central PMCID: PMC5767911.
17: Wei X, Zhang T, Yao Y, Zeng S, Li M, Xiang H, Zhao C, Cao G, Li M, Wan R, Yang P, Yang J. Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD. Exp Eye Res. 2018 Mar;168:2-11. doi: 10.1016/j.exer.2017.12.009. Epub 2017 Dec 25. PubMed PMID: 29284110.
18: Kudo M. Lenvatinib in Advanced Hepatocellular Carcinoma. Liver Cancer. 2017 Nov;6(4):253-263. doi: 10.1159/000479573. Epub 2017 Aug 29. PubMed PMID: 29234629; PubMed Central PMCID: PMC5704706.
19: Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma. Intern Med. 2018 Apr 1;57(7):1015-1019. doi: 10.2169/internalmedicine.9593-17. Epub 2017 Dec 8. PubMed PMID: 29225265.
20: Morelli S, Puxeddu E. Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient. Drugs Context. 2017 Jul 26;6:212310. doi: 10.7573/dic.212310. eCollection 2017. PubMed PMID: 29167691; PubMed Central PMCID: PMC5699105.
